|
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Food and Drug Administration
1401 Rockville Pike
Rockville, MD 20852-1448
August 27, 1999
Our Reference Number: 99-0909
Roberta L. McKee, Ph.D.
Merck & Co., Inc.
P.O. Box 4
Sumneytown Pike
West Point, PA 19486
Dear Dr. McKee:
The Supplement to your License Application for Hepatitis B (Recombinant) Vaccine, to include the use of a preservative-free [---] µg/mL bulk alum product for the introduction of preservative-free pediatric/adolescent final containers (5 µg/0.5 mL vials), has been approved. This information will be included in your License Application file.
Expiration dating will be 36 months for the 5 µg/0.5 mL thimerosal free final container vial presentation.
We acknowledge the commitment outlined in your letter of August 26, 1999, to incorporate sterility testing at each specified time interval of 0, 3, 6, 9, 12, 24, and 36 months as stated in your stability testing schedule and to report the real time stability data to CBER as they become available rather than in your Product Annual Report.
We also acknowledge your withdrawal of the [------------------------------ ----------------] of the current submission and understand that you will submit another supplement at a later time when stability data and appropriate demonstration of [---------------- ------------] are available.
Please submit three copies of final printed labeling, under label review number 19990811002, at the time of use and include part II of the label transmittal form with completed implementation information.
Sincerely yours,
--- signature ---
Peter A. Patriarca, M.D.
Director
Division of Viral Products
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research
|
